Zepbound Maintenance Dose After Goal Weight: What the Label and Trials Say

Zepbound's label lists 5 mg, 10 mg and 15 mg once weekly as the maintenance doses for weight reduction and long-term maintenance, and it names no separate "after goal weight" dose ¹. One trial has tested stepping down. In SURMOUNT-MAINTAIN, people cut from 10 or 15 mg to 5 mg kept most of their loss, but about a quarter needed rescue treatment ².

That trial is new, published in 2026, and it changes the honest answer to a question people have been asking since the drug launched. It does not answer the microdosing version of the question, and the difference matters.

What maintenance doses does the Zepbound label allow?

The label's dosing section is short. You start at 2.5 mg once weekly, step up by 2.5 mg no sooner than every four weeks, and land on a maintenance dose of 5, 10 or 15 mg for weight reduction and long-term maintenance; 15 mg is the ceiling ¹. (For obstructive sleep apnea the maintenance dose is 10 or 15 mg.) There is no instruction to drop to a lower dose once you reach a goal, and no lower "maintenance after maintenance" rung.

Two details are easy to miss. First, 5 mg is a labeled maintenance dose in its own right, so a clinician who keeps you there, or moves you back to it, is working inside the label. Second, 2.5 mg is not. The label says the 2.5 mg dose "is for treatment initiation and is not approved as a maintenance dosage" ¹, and Lilly repeats the point on its self-pay page ⁷. Anything below 2.5 mg is not a Zepbound dose at all; it is something a person measures out themselves, which is the territory covered in what microdosing Zepbound actually involves.

What happened when people stopped?

Before the step-down trial, the evidence was about stopping, and it was consistent across both major drugs.

In SURMOUNT-4, 670 adults who had lost an average of 20.9% of their weight over 36 weeks on their maximum tolerated tirzepatide dose (10 or 15 mg) were randomized to keep taking it or switch to placebo for another 52 weeks. The tirzepatide group lost a further 5.5%. The placebo group regained 14.0%. At the end, 89.5% of those still on the drug had kept at least 80% of their earlier loss, against 16.6% of those taken off it ³.

Semaglutide showed the same shape. In STEP 4, people who had reached 2.4 mg and lost 10.6% over 20 weeks either continued or switched to placebo for 48 weeks; the continuers lost another 7.9% while the placebo group regained 6.9% ⁴. In the STEP 1 extension, people taken off semaglutide regained 11.6 of the 17.3 percentage points they had lost within a year, about two-thirds of it, and most cardiometabolic improvements drifted back toward baseline ⁵.

So "stop at goal weight" was never the evidence-based option. The open question was whether something between full dose and nothing would hold.

Can you step down instead of stopping?

SURMOUNT-MAINTAIN is the first randomized test of exactly that. It ran at 20 US sites. Adults with obesity first spent 60 weeks on open-label tirzepatide at their maximum tolerated dose, 10 or 15 mg. Then 378 of them were randomized to one of three paths for 52 more weeks: stay on that dose, drop to 5 mg, or switch to placebo. The trial was funded by Lilly ².

At week 112, counted from the very start of treatment:

Read it in plain terms. Stepping down to 5 mg kept people well below their starting weight, at a 16.6% average loss, and far better off than stopping, at 9.9%. It did not hold the line as well as staying on the full dose, which ended at 21.9%. The rescue figures tell the same story from another angle. The protocol let anyone who regained more than half of what they had lost restart tirzepatide from week 84. That happened to 8% of the full-dose group, 25% of the 5 mg group and 67% of the placebo group ².

The authors' own conclusion is careful: reducing to 5 mg "might provide a valuable alternative to discontinuation, although individuals' treatment response might vary" ². One in four people on 5 mg regained enough to need rescue. That is a real minority, and nobody can tell you in advance whether you would be in it.

What this does not tell a microdoser

SURMOUNT-MAINTAIN tested 5 mg, the lowest labeled maintenance dose. It did not test 2.5 mg, and it did not test any fraction of a milligram. If 5 mg let a quarter of people slide far enough to need rescue, the trial gives no reason to expect that a dose a fraction of that size would do better, and some reason to expect worse.

That matters because the maintenance pitch for a microdose usually borrows the logic of a step-down, then quietly moves the number. "Maintenance takes less drug than loss" now has a trial behind it at 5 mg. "Maintenance takes a microdose" still has none. We go through the wider evidence on that in using a microdose to maintain weight loss, and if your plan is to come off entirely, how to taper off a GLP-1 covers what a taper can and cannot do.

Wegovy maintenance dose, for comparison

Wegovy's label is more specific about choice. For weight reduction in adults the maintenance dose is 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended. For patients who tolerate 2.4 mg for at least four weeks and need more weight reduction, the dose may go up to 7.2 mg ⁶. So the semaglutide label already names a lower maintenance option, 1.7 mg, but no trial like SURMOUNT-MAINTAIN has tested stepping down to it after goal weight.

What staying on a maintenance dose costs for a year

Cost is usually why people want to step down, so it is worth seeing what the label doses cost on the manufacturers' own self-pay programs. LillyDirect defines a Zepbound "month" as 28 days (four single-dose vials or one four-dose KwikPen), so a year of weekly doses is 13 fills. NovoCare defines a Wegovy month as one box of four pens, which also works out to 13 fills a year ^7,8.

On these programs the step from 10 or 15 mg down to 5 mg saves $650 a year if you refill on time, and $3,900 a year if you would otherwise pay Lilly's regular rate for the higher doses. That is a meaningful saving. It is also a smaller one than the gap between brand maintenance and the cheapest compounded plans, which is the comparison most people are really making. We lay out every brand dose and price in Zepbound and Wegovy self-pay prices by dose.

Where low-dose tirzepatide plans are sold

Several telehealth companies sell compounded tirzepatide under a named low-dose or microdose label, among them Enhance MD and Telos Rx. Compounded tirzepatide is not FDA-approved, a named "microdose" product usually states no milligram figure, and none of these plans is the 5 mg dose SURMOUNT-MAINTAIN tested. If you are pricing one, the question to ask is whether the plan actually charges less when you take less; the cheapest tirzepatide plans for a small dose are sorted on that basis.

Any change to a maintenance dose belongs in a conversation with the clinician who prescribes it, with your weight tracked afterward. The trial result gives that conversation a real number to start from: 5 mg is a tested step down, and it is not a guarantee.